Summary of First Four Prostate, Lung, Colorectal, and Ovarian Screening Roundsa
| T0 (Baseline) | T1 | T2 | T3 | |
| Number Tested (PSA or DRE) | 34,262 | 32,696 | 31,697 | 30,544 |
| PSA positive (>4 ng/mL) (%) | 7.9 | 7.7 | 8.2 | 8.8 |
| DRE positive (%) | 7.2 | 6.8 | 7.3 | 7.6 |
| Either test positive (%) | 14.0 | 13.5 | 14.4 | 15.1 |
| Biopsies and Cancers | ||||
| PSA >4 ng/mL | 2,718 | 2,502 | 2,593 | 2,676 |
| Cancers | 487 | 308 | 270 | 281 |
| Cancers/1,000 screened | 14.2 | 9.4 | 8.5 | 9.3 |
| DRE abnormal and PSA ≤4 ng/mL | 2,083 | 1,923 | 1,973 | 1,943 |
| Cancers | 62 | 67 | 71 | 57 |
| Cancers/1,000 screened | 1.8 | 2.1 | 2.3 | 1.9 |
| PSA >4 ng/mL or DRE abnormal | 4,801 | 4,425 | 4,566 | 4,619 |
| Cancers | 549 | 375 | 341 | 338 |
| Cancers/1,000 screened | 16.0 | 11.5 | 10.8 | 11.1 |
| DRE = digital rectal exam; PSA = prostate-specific antigen; T = tumor. | ||||
| aAdapted from Grubb et al.[46] |
References
- Grubb RL 3rd, Pinsky PF, Greenlee RT, et al.: Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 102 (11): 1524-30, 2008. [PUBMED Abstract]
